Fisher Asset Management LLC Has $653,000 Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Fisher Asset Management LLC lowered its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 13.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 26,124 shares of the company’s stock after selling 4,101 shares during the quarter. Fisher Asset Management LLC’s holdings in Kiniksa Pharmaceuticals were worth $653,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. CWM LLC increased its position in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after buying an additional 1,998 shares in the last quarter. nVerses Capital LLC acquired a new stake in Kiniksa Pharmaceuticals in the third quarter valued at approximately $80,000. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals during the first quarter valued at approximately $71,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Kiniksa Pharmaceuticals during the second quarter worth approximately $100,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock worth $195,000 after purchasing an additional 3,076 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This represents a 53.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eben Tessari sold 17,500 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the sale, the chief operating officer now owns 116,975 shares of the company’s stock, valued at approximately $2,923,205.25. The trade was a 13.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 95,192 shares of company stock worth $2,479,390 in the last quarter. 54.57% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Evercore ISI upped their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Jefferies Financial Group assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, JPMorgan Chase & Co. lifted their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $36.60.

Kiniksa Pharmaceuticals Price Performance

KNSA opened at $22.08 on Friday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $15.82 and a fifty-two week high of $28.15. The firm has a market capitalization of $1.59 billion, a P/E ratio of -157.70 and a beta of 0.35. The company’s 50-day moving average is $23.95 and its 200 day moving average is $22.93.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals’s quarterly revenue was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS. On average, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.